Chemed Corp (CHE)
Stock · NYSE · Health Care
$512.38as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
CHE Signal Track Record
How signals performed across all stocks →What CHE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +1.1% | 50% | September 18, 2026 |
| 200-Day Moving Average Touch | 27 | -0.0% | 44% | May 29, 2026 |
| Bollinger Band Breakdown | 24 | +1.3% | 58% | August 27, 2026 |
| Bollinger Band Breakout | 22 | +2.1% | 59% | July 29, 2026 |
| Any 20-session window (baseline) | -0.1% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CHE
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential…
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- Employees
- 15,811
- Website
- www.chemed.com/
Fundamentals
- 1-day range
- $498.79$514.48
- Market cap
- $7.18B
- P/E (trailing)
- 24.34
- P/E (forward)
- 18.61
- EPS (trailing)
- $19.92
- Dividend yield
- 0.28%
- Beta
- 0.51
- Avg. volume
- 160.9K
- Ex-dividend date
- August 17, 2026
- Dividend pay date
- September 3, 2026
How Chemed Corp Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Chemed Corp Competitors
Chosen by industry and closest market cap.
- CHEChemed Corp$512.38▼ 0.59%Market cap $7.18BP/E 24.34$365.21$557
- HIMSHims & Hers Health Inc. Class A Common Stock$28.07▼ 4.46%Market cap $6.87BP/E —$13.74$65.3
- LFSTLifeStance Health Group Inc. Common Stock$11.74▼ 5.09%Market cap $4.13BP/E 93.42$4.77$13.56
- OPCHOption Care Health Inc. Common Stock$31.2▼ 0.06%Market cap $3.54BP/E 22.23$18.01$36.8
- PRVAPrivia Health Group Inc. Common Stock$22.52▼ 0.44%Market cap $2.77BP/E 102.74$18.92$28.82
- BTSGBrightSpring Health Services Inc. Common Stock$60.87▼ 2.39%Market cap $11.99BP/E 33.72$28.71$73.75
- ADUSAddus HomeCare Corporation Common Stock$115.98▼ 0.44%Market cap $2.22BP/E 20.70$87.95$124.44
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CHE Chemed Corp | $7.18B | 24.34 | $512.38 | ▼ 0.59% | $365.21$557 |
| HIMS Hims & Hers Health Inc. Class A Common Stock | $6.87B | — | $28.07 | ▼ 4.46% | $13.74$65.3 |
| LFST LifeStance Health Group Inc. Common Stock | $4.13B | 93.42 | $11.74 | ▼ 5.09% | $4.77$13.56 |
| OPCH Option Care Health Inc. Common Stock | $3.54B | 22.23 | $31.2 | ▼ 0.06% | $18.01$36.8 |
| PRVA Privia Health Group Inc. Common Stock | $2.77B | 102.74 | $22.52 | ▼ 0.44% | $18.92$28.82 |
| BTSG BrightSpring Health Services Inc. Common Stock | $11.99B | 33.72 | $60.87 | ▼ 2.39% | $28.71$73.75 |
| ADUS Addus HomeCare Corporation Common Stock | $2.22B | 20.70 | $115.98 | ▼ 0.44% | $87.95$124.44 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Roto-Rooter Buys Largest Franchisee TerritoryYahoo · 9/16/2026
- Chemed’s Subsidiary Roto-Rooter Services Acquires Independent Roto-Rooter Franchise For $60.6MBenzinga · 9/16/2026
- Chemed Corporation (CHE) Presents at 2026 Jefferies Healthcare Services and Technology Conference TranscriptSeekingAlpha · 9/15/2026
Insider Activity
Insider Actions →- MCNAMARA KEVIN J · August 21, 2026 · Sale2.0K @ $541.16
- LEE SPENCER S · August 21, 2026 · Sale1.0K @ $541.04
- Judkins Brian C · August 10, 2026 · Option Exercise6.8K @ $445.35
- Judkins Brian C · August 10, 2026 · Tax Withholding5.9K @ $548.96
- Wherley Joel L · August 5, 2026 · Option Exercise2.6K @ $445.35
- Wherley Joel L · August 5, 2026 · Tax Withholding2.3K @ $542.62
- MCNAMARA KEVIN J · August 3, 2026 · Option Exercise2.0K @ $445.35
- MCNAMARA KEVIN J · August 3, 2026 · Sale2.0K @ $539.51
- MCNAMARA KEVIN J · July 31, 2026 · Tax Withholding19.8K @ $529.22
- MCNAMARA KEVIN J · July 31, 2026 · Option Exercise2.0K @ $445.35
- GRACE PATRICK P · July 31, 2026 · Sale190 @ $532
- LINDELL ANDREA R · June 9, 2026 · Sale1.3K @ $447.33
- WALSH GEORGE J III · May 29, 2026 · Sale500 @ $437.83
- Eileen P. McCarthy · May 18, 2026 · Grant386 @ $440.77
- Mount John Meredith Jr. · May 18, 2026 · Grant386 @ $440.77
Institutional Ownership
March 31, 2026
- Total shares held
- 11.69M
- Total value held
- $4.10B
- Institutional holders
- 477
- Unknown1.34M
- Unknown636.1K
- Unknown462.2K
- Unknown415.6K
- Unknown411.0K
- Unknown306.9K
- Unknown301.6K
- Unknown279.7K
- Unknown250.1K
- Unknown247.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Chemed to report Q3 2026 earnings on October 27
Chemed Corp is scheduled to release its third-quarter 2026 earnings on October 27, with a conference call following on October 28. This upcoming report is the primary focus for investors, as it will provide the latest financial results for the company. While the stock currently trades below its average analyst target price, the near-term attention remains on the details of this earnings announcement.
Chemed to report Q3 2026 earnings on October 27. Chemed Corp is scheduled to release its third-quarter 2026 earnings on October 27, with a conference call following on October 28. This upcoming report is the primary focus for investors, as it will provide the latest financial results for the company. While the stock currently trades below its average analyst target price, the near-term attention remains on the details of this earnings announcement.